Lilly, who holds the marketing authorization for the diabetes drug ‘Trulicity (dulaglutide),’ which has been distributed by Boryung since 2016, will directly distribute the drug in Korea from next year.

With the launch of the diabetes and obesity drug Mounjaro (tirzepatide) expected next year, it is expected that this change of distributors will have an impact.

According to industry sources on the 9th, Lilly Korea told its customers that the distributor for Trulicity 0.75mg/0.5ml and 1.5mg/0.5ml disposable pens will be changed from Boryung to Lilly from next year.

Boryung and Lilly signed a joint sales agreement in June 2016 to market and sell Trulicity in Korea. Under